Analysis About Clinical Efficacy And Safety Of Different Doses Tirofiban In Patients With Acute Cornary Syndrome Undergoing PCI

Objective:To investigate the values and safety in different dose of Tirofiban in patients with acute coronary syndrome(ACS) undergoing percutaneous coronary intervention (PCI).Methods:Totally143patients suffered from acute coronary syndromes between were selected and divided into two groups according to dose(full dose and half-dose). Two groups routinely given standardized treatment of coronary heart disease and give Tirofiban10ug/kg loading dose in3min intravenous injection, Then the full-dose group and half-dose groups, respectively,to0.15ug· kg-1·min-1and0.075ug·kg-1·min-1continuous intravenous infusion48h. Two groups were compared platelet count, creatine kinase, creatine kinase isoenzyme magnitude of MACE (major adverse cardiac events) rates, security indexes.Based clinical characteristics and TIMI blood flow grade after PCI, left ventrieular ejection fraction(LVEF), the level of CK-MB, major adverse cardiac events rates(MACE) during hospital after PCI were analyzed.Results:There was no statistical significance in the clinical data between the two groups. There was no statistical significance in the rate of IRA achieved TIMI3after operation,the level of CK-MB and heart function and early MACE between the two groups.Conclusion:Theresults suggest that Tirofiban is a safe and tolerabletherapy drug for ACS patients to PCI,To have the dose halved will not increase incidence rate ofheart. blood vessel event.